Bioject Medical (BJCT) 8-K Financial statements and exhibits

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):            October 27, 2003

BIOJECT MEDICAL TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Oregon	93-1099680
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
211 Somerville Road, Route 202 North, Bedminster, NJ	07921
(Address of principal executive offices)	(Zip Code)
Registrant’s telephone number, including area code:  (908) 470-2800

BIOJECT MEDICAL TECHNOLOGIES INC.

FORM 8-K

INDEX

Item	Description
Item 7.	Financial Statements and Exhibits
Item 12.	Results of Operations and Financial Condition
Signatures

1

Item 7.  Financial Statements and Exhibits

(c) Exhibits

This list is intended to constitute the exhibit index:

99.1Press release dated October 27, 2003 regarding Bioject’s third quarter 2003 revenue and earnings.

Item 12.  Results of Operations and Financial Condition

On October 27, 2003, Bioject announced a net loss of $2.4 million, or $(0.22) per share, on revenue of $1.4 million for its third quarter of 2003 ended September 30, 2003.

A copy of the October 27, 2003 press release is included as exhibit 99.1 hereto.  This exhibit is not filed, but is furnished pursuant to Item 12. (a) of Form 8-K.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 27, 2003	BIOJECT MEDICAL TECHNOLOGIES INC.
	(Registrant)
	/s/ JAMES O’SHEA
	James O’Shea
	Chairman of the Board, Chief Executive Officer
	and President (Principal Executive Officer)
	/s/ JOHN GANDOLFO
	John Gandolfo
	Chief Financial Officer and Vice President of Finance
	(Principal Financial and Accounting Officer)

3